BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34168446)

  • 21. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
    Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
    World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
    Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
    Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
    Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
    Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.
    Yorita K; Ohno A; Nishida T; Kondo K; Ohtomo T; Kataoka H
    BMC Res Notes; 2019 Nov; 12(1):741. PubMed ID: 31706332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
    Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
    J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved method increases sensitivity for circulating hepatocellular carcinoma cells.
    Liu HY; Qian HH; Zhang XF; Li J; Yang X; Sun B; Ma JY; Chen L; Yin ZF
    World J Gastroenterol; 2015 Mar; 21(10):2918-25. PubMed ID: 25780289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.
    Yan D; He Q; Chen Y; Wang L; Zhang X
    J Clin Lab Anal; 2011; 25(2):113-7. PubMed ID: 21438004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
    Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
    Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.
    Guo W; Yang XR; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang X; Zhou J; Fan J
    Clin Cancer Res; 2014 Sep; 20(18):4794-805. PubMed ID: 25009297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
    Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
    Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
    Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
    Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
    Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology.
    Zaakook M; Ayoub M; Sinna EA; El-Sheikh S
    J Egypt Natl Canc Inst; 2013 Dec; 25(4):173-80. PubMed ID: 24207089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
    Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
    J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
    Kelley RK; Magbanua MJ; Butler TM; Collisson EA; Hwang J; Sidiropoulos N; Evason K; McWhirter RM; Hameed B; Wayne EM; Yao FY; Venook AP; Park JW
    BMC Cancer; 2015 Mar; 15():206. PubMed ID: 25884197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.